CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 81 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $321,000 | +221.0% | 10,804 | +93.1% | 0.00% | – |
| Q2 2023 | $100,000 | +85.2% | 5,595 | +64.8% | 0.00% | – |
| Q1 2023 | $54,000 | -57.1% | 3,394 | -50.7% | 0.00% | – |
| Q4 2022 | $126,000 | +530.0% | 6,890 | +584.2% | 0.00% | – |
| Q3 2022 | $20,000 | +53.8% | 1,007 | +52.1% | 0.00% | – |
| Q2 2022 | $13,000 | -80.9% | 662 | -78.6% | 0.00% | – |
| Q1 2022 | $68,000 | -75.6% | 3,088 | -68.6% | 0.00% | – |
| Q4 2021 | $279,000 | +304.3% | 9,823 | +199.8% | 0.00% | – |
| Q3 2021 | $69,000 | +25.5% | 3,277 | +13.1% | 0.00% | – |
| Q2 2021 | $55,000 | +103.7% | 2,897 | +62.2% | 0.00% | – |
| Q1 2021 | $27,000 | +237.5% | 1,786 | +215.0% | 0.00% | – |
| Q4 2020 | $8,000 | +700.0% | 567 | +1432.4% | 0.00% | – |
| Q3 2020 | $1,000 | -91.7% | 37 | -94.9% | 0.00% | – |
| Q2 2020 | $12,000 | +200.0% | 723 | +162.0% | 0.00% | – |
| Q1 2020 | $4,000 | -66.7% | 276 | -42.7% | 0.00% | – |
| Q4 2019 | $12,000 | +100.0% | 482 | +16.1% | 0.00% | – |
| Q3 2019 | $6,000 | -40.0% | 415 | 0.0% | 0.00% | – |
| Q2 2019 | $10,000 | +11.1% | 415 | 0.0% | 0.00% | – |
| Q1 2019 | $9,000 | +800.0% | 415 | +1283.3% | 0.00% | – |
| Q4 2018 | $1,000 | -88.9% | 30 | -90.9% | 0.00% | – |
| Q3 2018 | $9,000 | – | 328 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |